Reply to letter comments on: Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, phase III umbrella trial (SAFIR-ABC10-Precision Medicine).

2 In fact, in the ClarIDHy trial, 70% of patients in the placebo arm switched to the experimental treatment [the isocitrate dehydrogenase 1 (IDH1) inhibitor ivosidenib], so that the numerical OS benefit [a secondary endpoint, progression-free survival (PFS) having logically been chosen as the primary endpoint] did not reach statistical significance [median 10.3 versus 7.5 months, hazard ratio (HR) 0.79, 95% confidence interval (CI) 0.56-1.12, P = 0.09].

also in 111,027 other papers